lncRNA HIF1A‑AS2: A potential oncogene in human cancers (Review)
- Yang Liu
- Yunyan Zhang
- Cha Chen
- Youqiang Li
Affiliations: The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, P.R. China, Department of Stomatology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510000, P.R. China, Department of Laboratory Medicine, The Affiliated Hexian Memorial Hospital of Southern Medical University, Guangzhou, Guangdong 511400, P.R. China
- Published online on: August 13, 2021 https://doi.org/10.3892/br.2021.1461
Copyright: © Liu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Long non‑coding RNAs (lncRNAs) are transcripts that are >200 nucleotides, but with no open reading frame. An increasing number of lncRNAs have been identified following the development of second‑generation sequencing technologies, and they have since become a research hotspot. Functionally, they play a vital role in tumor progression, including in tumor proliferation, migration, invasion, apoptosis and acquisition of drug resistance. They regulate gene expression primarily through interaction with DNA, RNA and proteins at the epigenetic, transcriptional and post‑transcriptional levels. Endogenous hypoxia‑inducible factor 1α antisense RNA 2 (lncRNA HIF1A‑AS2) is aberrantly expressed and involved the development/progression of various types of tumors, such as bladder cancer, glioblastoma, breast cancer and osteosarcoma. It plays a vital role in the proliferation, apoptosis, migration, invasion and epithelial‑mesenchymal transformation of various tumor cells. This review summarizes the current body of knowledge on the biological functions and related molecular mechanisms of lncRNA HIF1A‑AS2 in the development/progression of human tumors and other diseases.